Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies (Q46803174)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies |
scientific article |
Statements
1 reference
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies (English)
1 reference
Monica M Mita
1 reference
Alain C Mita
1 reference
Quincy S Chu
1 reference
Eric K Rowinsky
1 reference
Gerald J Fetterly
1 reference
Michelle Goldston
1 reference
Amita Patnaik
1 reference
Lesley Mathews
1 reference
Alejandro D Ricart
1 reference
Theresa Mays
1 reference
Heather Knowles
1 reference
Victor M Rivera
1 reference
Jeff Kreisberg
1 reference
Camille L Bedrosian
1 reference
Anthony W Tolcher
1 reference
1 January 2008
1 reference
1 reference
26
1 reference
3
1 reference
361-367
1 reference
Identifiers
1 reference
1 reference